Background: Thymic carcinoma is a rare cancer with an aggressive clinical presentation and
no organotypic symptoms. Despite using platinum-based chemotherapy as first-line …

Objectives The main objective of this report was to detail the long-term follow-up data from
the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with …

Objective For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been
established in second-or further-line settings. The aim of this study was to evaluate the …

Background Thymic carcinoma is a rare malignant disease. Standard treatments have not
been established for patients with advanced or metastatic thymic carcinoma previously …

Simple Summary Thymic carcinoma is identified as thoracic neoplasm having low sensitivity
to systemic chemotherapy. As first-line setting, platinum-based chemotherapy is …

Background Thymic carcinoma is a rare disease with an incidence of around 0.5 cases per
million with a poor prognosis. The aim of this study was to assess patient outcomes with …

Background Thymic carcinomas (TCs) are rare aggressive tumors with no standard first‐line
treatment. This study was conducted to determine the optimal chemotherapy regimen for …

BACKGROUND: Thymic carcinoma is a very rarely encountered neoplasm and no optimal
chemotherapeutic regimen has been established yet. METHODS: The records of previously …

Objective Thymic carcinoma is a rare mediastinal neoplasm. While platinum-based
chemotherapy has been reported to be effective for advanced thymic carcinoma in a first-line …

Thymic carcinoma (TC) is a rare cancer and patients failing initial chemotherapy
(relapse/refractory) face limited therapeutic options given no approved options or consensus …